Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

This is a phase 2 multicenter national interventional pharmacological study aimed at determining the efficacy of a fixed duration treatment with ibrutinib and obinutuzumab in terms of uMRD in the BM at the end of treatment (+30 Days follow-up). Treatment with ibrutinib and obinutuzumab will be administered according to the following schedule: Ibrutinib 420 mg QD for 24 months (Cycles 1-24) Obinutuzumab starting from Cycle 13 Day 1 (100 mg Cycle 13 Day 1, 900 mg Cycle 13 Day 2, 1000 mg Cycle 13 Days 8 and 15, 1000 mg Cycles 14-18 Day 1). At the end of Cycle 24 all responding patients will di

Trial Details

NCT ID
NCT04908228
Phase
PHASE2
Sponsor
Paolo Ghia
Status
RECRUITING
Cancer Type
Chronic Lymphocytic (CLL) Leukemia
Interventions
  • Ibrutinib and obinutuzumab
Locations (sample)
  • Milan, MI, Italy|42.78235,12.59836

Key Eligibility Criteria

  • Age ≥18 years
  • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets iwCLL diagnostic criteria
  • Previously untreated active disease requiring treatment per iwCLL criteria
  • ECOG PS 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Lymphocytic (CLL) Leukemia Trials on Trialify →